| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司的主营业务为自有药品的研发、生产和销售及代理药品的销售。目前，公司已发展成为以儿童用药和慢性病用药等领域为核心，其他类别药物为补充，集医药研发、生产、销售为一体的现代化医药企业集团。 一品红制药共拥有94个品种133个药品注册批件，其中独家产品11个，包括9个独家品种和2个独家剂型。国家中药保护品种2个，专利品种13个。进入国家医保目录的品种57个，国家基药品种11个，多个品种进入地方医保和地方基药目录。公司盐酸克林霉素棕榈酸酯分散片为广东省高新技术产品、广东省医药行业优秀产品品牌，注射用促肝细胞生长素为广东省高新技术产品、广东省医药行业专利、原研药优秀产品品牌，馥感啉口服液、尿清舒颗粒为国家中药保护品种、广东省高新技术产品，注射用脑蛋白水解物为广东省高新技术产品。一品红制药拥有片剂、颗粒剂、合剂、中药前处理和提取车间（口服制剂）、冻干粉针剂、洗剂、中药前处理及提取车间（外用制剂）等剂型的生产线及相应的GMP认证。 公司具有较强的自主创新能力，一品红制药为广州市人力资源和社会保障局认定的博士后创新实践基地、广东省科学技术厅认定的广东省生化制剂工程技术研究中心、广东省省级企业技术中心、广东省高新技术企业协会认定的广东省创新型企业。一品红制药被广东省科技厅、广东省财政厅、广东省国税局、广东省地税局联合认定为高新技术企业。2015年，一品红制药被广州市开发区管委会评选为“瞪羚企业20强”。2016年，一品红制药在第33届全国医药工业信息年会上被评选为“2016年中国医药工业最具投资价值企业（非上市）”，一品红制药在“2016年（第八届）中国医药战略峰会”上被中国医药工业研究总院评选为“2016年中国创新力医药企业”。 | ||||||||||||||||||||||||
| Main Business | 专注于药品研发、生产、销售的医药创新企业，产品聚焦于儿童药和慢病药领域，主要从事处方药研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 李捍雄 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 张明渊 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 广东正中珠江会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 020-28877623 | ||||||||||||||||||||||||
| Fax No | 020-28877668 | ||||||||||||||||||||||||
| Website | www.gdyph.com | ||||||||||||||||||||||||
| zqb@gdyph.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 16/11/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.420 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.210 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.554 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 8.795B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |